Editorial: Toward Personalized Treatment for Systemic Juvenile Idiopathic Arthritis

Vastert, Sebastiaan J.; Nigrović, Peter A.

doi:10.1002/art.40501

Cited by 7 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1][2][3][4][5] These drugs have been mainly investigated in controlled clinical trials in children, including systemic juvenile idiopathic arthritis (sJIA). [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22] However, due to a lower prevalence of disease, a lack of standardised classification criteria and outcome measurements, only a few studies were have been performed in adults so far. [23][24][25][26][27][28][29][30][31][32][33][34][35][36] Because of a similar pathogenesis, broadly overlapping symptoms and organ involvement,…”

Section: Introductionmentioning

confidence: 99%

Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

et al. 2020

View full text Add to dashboard Cite

BackgroundInhibition of interleukin (IL)-1 represents a promising treatment option in adult-onset Still's disease (AOSD).ObjectiveTo investigate the efficacy and safety of canakinumab in patients with AOSD and active joint involvement by means of a multicentre, double-blind, randomised, placebo-controlled trial.MethodsPatients with AOSD and active joint involvement (tender and swollen joint counts of ≥4 each) were treated with canakinumab (4 mg/kg, maximum 300 mg subcutaneous every 4 weeks) or placebo. The primary endpoint was the proportion of patients with a clinically relevant reduction in disease activity at week 12 as determined by the change in disease activity score (ΔDAS28>1.2).ResultsAt enrolment, patients had high active disease with a mean DAS28(ESR) of 5.4 in the canakinumab and 5.3 in the placebo group, respectively. In the intention-to-treat analysis, 12 patients (67%) in the canakinumab group and 7 patients (41%) in the placebo group fulfilled the primary outcome criterion (p=0.18). In the per-protocol analysis, significantly higher American College of Rheumatology (ACR) 30% (61% vs 20%, p=0.033), ACR 50% (50% vs 6.7%, p=0.009) and ACR 70% (28% vs 0%, p=0.049) response rates were observed in the canakinumab group compared with the placebo group. Two patients in the canakinumab group experienced a serious adverse event.ConclusionAlthough the study was terminated prematurely and the primary endpoint was not achieved, treatment with canakinumab led to an improvement of several outcome measures in AOSD. The overall safety findings were consistent with the known profile of canakinumab. Thus, our data support indication for IL-1 inhibition with canakinumab in AOSD.

show abstract

Section: Introductionmentioning

confidence: 99%

Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

et al. 2020

View full text Add to dashboard Cite

show abstract

“…These subtypes differ in terms of treatment prescribed, as well as in disease severity, response to treatment and prognosis [17][18][19]. In addition, significant variation has been reported among patients of the same subtype [20,21]. Beside this patient-level heterogeneity, previous research found that early, aggressive treatment with biologicals was more effective in lowering disease activity compared to conservative delayed treatment [22], and that treat-to-target approaches proved to be superior to routine care in reaching remission [23,24].…”

Section: Introductionmentioning

confidence: 99%

Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system

Kip

Roock

Currie

et al. 2020

Expert Review of Pharmacoeconomics & Outcomes Research

Self Cite

View full text Add to dashboard Cite

Background: This study aims to quantify medication costs in juvenile idiopathic arthritis (JIA), based on subtype. Research design and methods:This study is a single-center, retrospective analysis of prospective data from electronic medical records of JIA patients, aged 0-18 years between 1 April 2011 and 31 March 2019. Patient characteristics (age, gender, subtype) and medication use were extracted. Medication use and costs were reported as: 1) mean total annual costs; 2) between-patient heterogeneity in these costs; 3) duration of medication use; and, 4) costs over the treatment course. Results: The analysis included 691 patients. Mean total medication costs were €2,103/patient/year, including €1,930/patient/year (91.8%) spent on biologicals. Costs varied considerably between subtypes, with polyarticular rheumatoid-factor positive and systemic JIA patients having the highest mean costs (€5,020/patient/year and €4,790/patient/year, respectively). Mean annual medication costs over the patient's treatment course ranged from <€1,000/year (71.1% of patients) to >€11,000/year (2.5% of patients). Etanercept and adalimumab were the most commonly used biologicals. Cost fluctuations over the treatment course were primarily attributable to biological use. Conclusions: Polyarticular rheumatoid-factor positive and systemic JIA patients had the highest mean total annual medication costs, primarily attributable to biologicals. Costs varied considerably between subtypes, individuals, and over the treatment course.

show abstract

“…Many experts believe that earlier modulation and suppression of cytokine release might potentially decrease the long-term impact of the disease, signifying the notion that a "window of opportunity" exists and leading to the successful management of such a disease [70]. Therefore, treatment is recommended as early as possible to achieve early control of inflammation and cytokine storm and subsequently avoidance of chronic arthritis [6].…”

Section:  Corticosteroidsmentioning

confidence: 99%

Current Review of Systemic Juvenile Idiopathic Arthritis: What Do Paediatricians Need to Know?

Albaker¹

2020

OJPed

View full text Add to dashboard Cite

Editorial: Toward Personalized Treatment for Systemic Juvenile Idiopathic Arthritis

Cited by 7 publications

References 13 publications

Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system

Current Review of Systemic Juvenile Idiopathic Arthritis: What Do Paediatricians Need to Know?

Contact Info

Product

Resources

About